AMGEN, INC. for AMGEN INC

Taxation/Internal Revenue Code TAX

Issues related to corporate and international tax, including regarding Public Law 115-97, Tax Cuts and Jobs Act Issues related to Puerto Rico H.R. 7527, Medical Manufacturing, Economic Development, and Sustainability Act of 2020 Proposed Rule, Guidance Related to the Foreign Tax Credit, Clarification of Foreign-Derived Intangible Income H.R. 6443, Securing the National Supply Chain Act of 2020 H.R. 6930, Manufacturing API, Drugs, and Excipients (MADE) in America Act of 2020 Issues related to OECD negotiations on the taxation of global income

Contacted: Treasury, Dept of; HOUSE OF REPRESENTATIVES; Commerce, Dept of (DOC); Executive Office of the President (EOP); Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); Office of Management & Budget (OMB); SENATE

Bills named: H.R. 6443 (116th), H.R. 6930 (116th), H.R. 7527 (116th)

Copyright/Patent/Trademark CPT

S. 124 Preserve Access to Affordable Generics Act Issues related to drug patents and exclusivities (no bill) H.R. 1520, Purple Book Continuity Act of 2019 H.R. 1499, Protecting Consumer Access to Generic Drugs Act of 2019 S. 1224, The Stop STALLING Act S. 1416, The Affordable Prescriptions for Patients Act S.659 - the Biologics Patent Transparency Act H.R. 938 Bringing Low-cost Options and Competition while Keeping Incentives for New Generics H.R. 5133 Affordable Prescriptions for Patients Through Promoting Competition H.R. 3991 Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act H.R. 2374 Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act H.R. 2375 Preserve Access to Affordable Generics and Biosimilars Act Patent eligibility reform, no specific bill

Contacted: Treasury, Dept of; Health & Human Services, Dept of (HHS); Commerce, Dept of (DOC); Executive Office of the President (EOP); SENATE; Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; Office of Management & Budget (OMB)

Bills named: S. 124 (116th), H.R. 3991 (116th), S. 1224 (116th), H.R. 938 (116th), H.R. 5133 (116th), H.R. 1499 (116th), S. 659 (116th), H.R. 2375 (116th), S. 1416 (116th), H.R. 1520 (116th), H.R. 2374 (116th)

Health Issues HCR

Biosimilars, no specific bill Prescription drug value issues, no specific bill FDA issues, no specific bill S. 657 Drug Price Transparency Act S. 658 Accelerated Drug Approval for Prescription Therapies Act S. 660 Efficiency and Transparency in Petitions Act S. 1895, Lower Health Care Costs Act, a comprehensive bill designed to improve healthcare transparency and reduce healthcare costs, including prescription drugs H.R. 1499, Protecting Consumer Access Generic Drugs Act H.R. 1344, Competitive Deals Resulting in Unleashed Generics and Savings (DRUGS) Act S. 1169, Ensuring Timely Access to Generics Act S. 1617, Second Look at Drug Patents Act H.R. 1520, Purple Book Continuity Act S. 977, Transparent Drug Pricing Act S. 102, Prescription Drug Price Relief Act S. 659, Biologic Patent Transparency Act H.R. 1503, Orange Book Transparency Act H.R. 2296, Fair Accountability and Innovative Research (FAIR) Drug Pricing Act S. 1664, Prescription Drug Price Reporting Act S.659 - the Biologics Patent Transparency Act Supply Chain Issues, no specific bill

Contacted: SENATE; HOUSE OF REPRESENTATIVES; Executive Office of the President (EOP); Health & Human Services, Dept of (HHS); Commerce, Dept of (DOC); Office of Management & Budget (OMB); Centers For Medicare and Medicaid Services (CMS); Treasury, Dept of

Bills named: H.R. 2296 (116th), S. 977 (116th), S. 1617 (116th), S. 658 (116th), H.R. 1344 (116th), H.R. 1520 (116th), S. 660 (116th), S. 1169 (116th), S. 1664 (116th), S. 1895 (116th), S. 659 (116th), S. 657 (116th), H.R. 1499 (116th), S. 102 (116th), H.R. 1503 (116th)

Medicare/Medicaid MMM

H.R. 133 - Consolidated Appropriations Act, 2021 H.R. 8406 - The HEROES 2.0 (Health and Economic Recovery Omnibus Emergency Solutions) Act and temporary access to Part B medicines at home H.R. 2693/S. 283 - Increasing Access to Osteoporosis Testing for Medicare Beneficiaries Act of 2019 H.R. 7647 - Preserving Patient Savings on Drug Costs Act H.R. 6179 - Increasing Access to Biosimilars Act of 2020 Executive Order on Lowering Drug Prices by Putting America First and Most Favored Nation (MFN) model Interim Final Rule H.R. 4597/S. 3466 - the ACCESS for Biosimilars Act of 2020 H.R. 3 - Lower Prescription Drug Costs Now Act H.R. 19/S. 3129 Lower Costs, More Cures Act S. 2543 Prescription Drug Pricing Reduction Act Issues related to the 340B program, no specific bill Home administration for Part B medicines due to COVID-19 Reimbursement for biologics/biosimilars Issues related to Part D redesign Executive Order on Lowering Prices for Patients by Eliminating Kickbacks to Middlemen Medicare Part D access issues for plan year 2020 and 2021, no specific bill Issues related to patient affordability issues, including copay cards, copay accumulators, National Benefit Payment Parameters Medicare End Stage Renal Disease Prospective Payment System (ESRD PPS) Proposed Rule (bundled payment for calcimimetics) Medicaid Value-Based Purchasing (VBP) Proposed Rule (Line Extensions & Manufacturer Co-pay Assistance) S. 551 Recovering Excessive Funds for Unused and Needless Drugs Act of 2019

Contacted: Health & Human Services, Dept of (HHS); Executive Office of the President (EOP); Centers For Medicare and Medicaid Services (CMS); Treasury, Dept of; HOUSE OF REPRESENTATIVES; Commerce, Dept of (DOC); SENATE; Office of Management & Budget (OMB)

Bills named: H.R. 133 (116th), H.R. 4597 (116th), S. 3129 (116th), H.R. 2693 (116th), S. 2543 (116th), H.R. 6179 (116th), H.R. 19 (116th), S. 283 (116th), S. 3466 (116th), S. 551 (116th), H.R. 3 (116th), H.R. 7647 (116th), H.R. 8406 (116th)